EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intracoronary nicorandil improves coronary microcirculatory function after primary PCI in first-episode STEMI: an angiography-derived evaluation using AMR and QFR

Qing Yu, Jie Lin, Jiashi Ding, Feifei Ye, Peng Li, Shikun Chen, Yiling Zhan, Wenqin Cai, Jiaqi Ou

Frontiers in Cardiovascular Medicine · 22.04.2026 · 13

DOI: 10.3389/fcvm.2026.1786130 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 22.04.2026. Verfasst von Qing Yu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Shaowu Municipal Hospital of Fujian Province, Shaowu, Fujian, China. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Microvascular dysfunction remains a major driver of adverse outcomes after ST-segment elevation myocardial infarction (STEMI) despite successful restoration of epicardial patency by primary percutaneous coronary intervention (PCI). Nicorandil has nitrate-like vasodilatory properties and ATP-dependent potassium channel (KATP)-opening properties, effects that may improve reperfusion physiology. However, its effects on wire-free, angiography-derived measures of microvascular function are not well defined. We evaluated whether intracoronary nicorandil administered during primary PCI improves angiography-derived microvascular function assessed by angiographic microcirculatory resistance (AMR) and quantitative flow ratio (QFR).

Methods

In this prospective, single-center randomized trial, 63 patients with first-episode STEMI undergoing primary PCI were allocated 1:1 to intracoronary nicorandil (2 mg after guidewire crossing; n = 32) or control (standard PCI; n = 31). The prespecified primary endpoint was final post-PCI AMR. QFR-derived indices, reperfusion measures [Thrombolysis in Myocardial Infarction (TIMI) flow grade, no-reflow, ST-segment resolution], hemodynamics, biomarkers, and clinical events were analyzed as secondary/exploratory outcomes, with multiplicity controlled using the Benjamini–Hochberg false discovery rate (FDR) where applicable.

Results

Baseline characteristics were balanced between groups. Compared with control, intracoronary nicorandil was associated with a higher rate of post-PCI TIMI grade 3 flow (96.9% vs. 74.2%; overall P = 0.013). Final AMR was significantly lower in the nicorandil group (1.4 ± 0.5 vs. 2.7 ± 0.5; P < 0.001). Vessel QFR and change in QFR ( Δ QFR) also favored nicorandil (both P < 0.001), whereas residual QFR showed only a borderline/non-significant difference after FDR correction (raw P = 0.027; q = 0.051). Peak creatine kinase-MB (CK-MB) and cardiac troponin I (cTnI) were numerically lower with nicorandil but not statistically different; left ventricular ejection fraction (LVEF) at 1 week was similar between groups. Rates of intra-procedural hypotension, in-hospital major adverse cardiovascular events (MACE), and MACE at 3-month follow-up did not differ.

Conclusions

In this pilot randomized study, intracoronary nicorandil administered during primary PCI was associated with improved angiography-derived surrogate indices of microvascular resistance and epicardial physiology without an observed increase in peri-procedural hemodynamic instability or short-term adverse events. These findings should be interpreted as exploratory and warrant confirmation in larger multicenter studies with longer follow-up and outcome-linked validation.

Schlagwörter

Stichwörter der Autor:innen

ST-segment elevation myocardial infarctionangiographic microcirculatory resistancecoronary microcirculationnicorandilprimary percutaneous coronary interventionquantitative flow ratio

Autor:innen und Institutionen

  • Department of Cardiology, Shaowu Municipal Hospital of Fujian Province, Shaowu, Fujian, China.
  • The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.

Zitieren

APA

Yu, Q., Lin, J., Ding, J., Ye, F., Li, P., Chen, S., Zhan, Y., Cai, W., & Ou, J. (2026). Intracoronary nicorandil improves coronary microcirculatory function after primary PCI in first-episode STEMI: an angiography-derived evaluation using AMR and QFR. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1786130

Vancouver

Yu Q, Lin J, Ding J, Ye F, Li P, Chen S, et al. Intracoronary nicorandil improves coronary microcirculatory function after primary PCI in first-episode STEMI: an angiography-derived evaluation using AMR and QFR. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1786130

BibTeX
@article{Yu2026,
  author = {Yu, Qing and Lin, Jie and Ding, Jiashi and Ye, Feifei and Li, Peng and Chen, Shikun and Zhan, Yiling and Cai, Wenqin and Ou, Jiaqi},
  title = {Intracoronary nicorandil improves coronary microcirculatory function after primary PCI in first-episode STEMI: an angiography-derived evaluation using AMR and QFR},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fcvm.2026.1786130}
}
Kostenlos starten →